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ABSTRACT
Objective: The aim of this study was to evaluate the effect of a voluntary protocol for selective
intrapartum chemoprophylaxis on the incidence of early onset group B streptococcal sepsis (GBS
EOS).
Methods: Cases ofGBS EOS were defined as a positiveGBS culture from a normally sterile fluid
obtained during the first 7 days of life. All cases of GBS EOS at an urban, university-affiliated
community hospital were reviewed during 2 time periods. The 2-year period before instituting a
resident education program to promote selective chemoprophylaxis (1988-89) was retrospectively
reviewed; the 2-year period after the education program was introduced (1990-91) was prospec-
tively recorded. The outcome measure was the incidence ofGBS EOS.
Results: The rateofGBS EOS was 7/14,335 deliveries (0.05%) before and 9/13,999 (0.064%) after
the introduction of the education program (observed difference between proportions 0.016%, 95%
confidence interval [CI] for the difference between the proportions -0.071% to 0.04%, P not
significant [NS]). The rate ofGBS EOS in preterm infants was 5/1,331 (0.376%) before and 3/1,297
(0.23%) afterward (observed difference between proportions 0.14%, 95% CI -0.28% to 0.56%, P
NS). The incidence ofGBS EOS did not decrease during the latter period due to failure of antepar-
tum cultures to predict intrapartum GBS colonization (2 cases); non-compliance with voluntary
recommendations to administer chemoprophylaxis (2 cases); failure of chemoprophylaxis or ther-
apy for intraamniotic infection to prevent neonatal infection (3 cases); and occurrence ofGBS EOS
in infants without risk factors (2 cases).
Conclusions:An education program for resident physicians regarding chemoprophylaxis forGBS
EOS did not significantly reduce the absolute incidence ofdisease. Alternative strategies are needed
that redress the causes offailure inherent in the current guidelines. Some cases ofGBS EOS are not
preventable because the parturient does not have risk factors that indicate chemoprophylaxis.
(C) 1994 Wiley-Liss, Inc.
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arly onset group B streptococcal sepsis (GBS
EOS) is the most common single cause of neo-
natal bacterial infection. In the past decade, the
risk factors associated with GBS EOS were identi-
fled and the effectiveness ofchemoprophylaxis dur-
ing the intrapartum period was demonstrated. 2’3
Antepartum cultures are poor predictors of intra-
partum colonization. 4’5 Furthermore, a reliable
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rapid diagnostic test for group B Streptococcus (GBS)
colonization that is feasible to use during the intra-
partum period is not yet available. 4’6 Thus, it is not
possible to identify patients colonized with GBS
when they present in labor. Therefore, Minkoff
and Mead
7 have recommended that all pregnant
patients with preterm labor (PTL) or preterm pre-
mature rupture of membranes (PROM) whose
GBS status is unknown receive chemoprophylaxis
until a negative culture is obtained. Pregnant pa-
tients with preterm PROM and/or PTL are easily
identified. They are at risk for GBS EOS and will
benefit from chemoprophylaxis.
3 We assessed the
absolute rate of GBS EOS before and after a spe-
cific resident education effort was begun at our
institution.
MATERIALS AND METHODS
This study was conducted at Cedars-Sinai Medical
Center, Los Angeles, CA, an urban, university-
affiliated, community medical center serving an
ethnically mixed population. During the time in-
terval from January 1, 1988, to December 31,
1989, there were no established management guide-
lines to prevent GBS EOS. From January 1, 1990,
selective chemoprophylaxis was strongly recom-
mended by the staff for patients with pregnancies
complicated by PTL (<37 weeks) or preterm
PROM. Term pregnancies complicated by pro-
longed ROM (P-ROM) (> 18 h) were also candi-
dates for chemoprophylaxis, although this was left
to the discretion of the physician.
7 Intrapartum
fever which was thought to represent intraamniotic
infection was an indication for antibiotic therapy
with ampicillin and gentamicin or a therapeutically
equivalent regimen. Compliance with the chemo-
prophylactic regimen was voluntary. The resident
education program consisted of a discussion of the
risk factors for GBS EOS and the benefits of
chemoprophylaxis during the daily work rounds
whenever the management of a patient with pre-
term PROM and/or PTL was discussed with the
resident staff. Chemoprophylaxis consisted ofampi-
cillin, 2 g q 6 h. Patients with penicillin allergy
received erythromycin.
7
We reviewed all identifiable cases of GBS EOS
to determine the incidence during both time peri-
ods. Obstetric data were reviewed to determine
whether the incidence of GBS EOS decreased in
patients with preterm delivery or preterm PROM.
Cases of GBS EOS were identified by reviewing
the ICDM-9 (International Classification of Dis-
eases, Clinical Modification, 9th Revision) dis-
charge diagnostic codes for GBS meningitis or GBS
bacteremia. A computerized microbiologic data-
base of all positive blood and cerebrospinal fluid
cultures for GBS was reviewed to identify addi-
tional cases. Medical records were available for all
the cases identified. Rates were compared using the
program Confidence Interval Analysis.
9
RESULTS
During the 2-year period (1988-89) before the
education program regarding GBS chemoprophy-
laxis, GBS EOS occurred in 7/14,335 deliveries
(0.05%) compared with the 2-year period (1990-
91) following the education program when there
were 9/13,999 (0.064%) (observed difference be-
tween proportions 0.0155%, 95% confidence in-
terval [CI] for the difference between the propor-
tions -0.071% to 0.04%, P not significant
[NS]). Among preterm deliveries fewer than 37
weeks gestation, there were 5/1,331 (0.376%) cases
of GBS EOS before and 3/1,297 (0.23%) after-
ward (observed difference between proportions
0.14%, 95% CI -0.28% to 0.56%, P NS)
(Table 1).
The overall incidence ofGBS EOS did not dif-
fer between the 2 periods. The incidence of GBS
EOS in PTL did not differ between the 2 time
periods. However, if one considers cases delivered
prior to 36 weeks gestation, then only case of
GBS EOS occurred in preterm infants during the
latter time period when chemoprophylaxis was con-
sistently recommended.
We did not determine the magnitude of compli-
ance with chemoprophylaxis among patients with
risk factors. Patients receiving expectant manage-
ment for preterm PROM receive care in a special
maternal-fetal medicine unit where the resident staff
and perinatologist make rounds twice daily and
review the management. We estimate that the com-
pliance rate for chemoprophylaxis in this group
approached 100%.
In the 1st study period (1988-89), 5 of the 7
cases were complicated by preterm PROM. One
could prospectively anticipate a prolonged (> 18 h)
time of ruptured membranes because expectant
management was attempted in all these cases. Two
additional cases of GBS EOS occurred in term
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TABLE I. Incidence of GBS EOS before and after the introduction of a protocol for chemoprophylaxis






Rate EOS/No. deliveries Rate
Preterm (<37 weeks gestation) 5/I,331
Term 2/I 3,004
Total 7114,335
1/266 (0.376%) 3/I,297 1/432 (0.23%)
I/6,502 (0.015%) 6/12,702 I/2,117 (0.047%)
I/2,048 (0.05%) 9/I 3,999 I/I,533 (0.064%)
pregnancies without risk factors. The incidence of
GBS EOS in term pregnancy was low even though
patients with risk factors did not usually receive
chemoprophylaxis in the absence of a defined pro-
tocol (Table 2).
During the 2nd period (1990-91), after the
introduction of’ a policy ofchemoprophylaxis, there
were 9 cases of GBS EOS. One case involved a
24-week gestation in which the precipitous delivery
precluded the administration of chemoprophylaxis
during the intrapartum period. The other 8 cases of
GBS EOS involved pregnancies of 36 weeks gesta-
tion or longer (Table 3). Three of the 8 had
P-ROM (>18 h) and received oxytocin induction
of labor for this indication. P-ROM could not be
predicted with certainty at the onset of labor, but
could have been anticipated in these 3 cases after 12
h ofROM (patients 3, 5, and 6, Table 3). One case
of GBS EOS was associated with ROM of 14 h
duration in a patient undergoing induction of labor
for post-dates pregnancy (patient 9, Table 3). Two
patients at term developed fever during labor: pa-
tient 9 was treated with ampicillin and gentamicin
65 min prior to delivery and patient 6 had penicil-
lin allergy and received cefoxitin and gentamicin 2
h prior to delivery (Table 3). Chemoprophylaxis is
most effective if administered at least 4 h prior to
delivery,
l0
In case, an antepartum vaginal culture ob-
tained 3 days prior to delivery was negative, al-
though the neonate was heavily colonized at the
time of delivery. The only risk factor in this case
was preterm delivery at 36 weeks gestation (patient
2, Table 3).
One patient had spontaneous labor after sponta-
neousROM and developed a fetal tachycardia. Ma-
ternal fever was detected during the cesarean sec-
tion for fetal distress. This case represents the
association of intrapartum fever with GBS EOS
(patient 8, Table 3). Two patients (4 and 7, Table
3) had no risk factors.
The 3 neonatal deaths during the 4-year study
occurred in preterm infants who did not receive
chemoprophylaxis (Tables 2, 3).
DISCUSSION
Randomized prospective studies have demonstrated
that GBS EOS can be prevented by chemoprophy-
laxis of colonized, high-risk parturients. 2’3 The
impact of selective chemoprophylaxis on the inci-
dence ofGBS EOS in a community hospital has not
been described outside prospective clinical trials.
Garland and Fliegner
ll achieved a reduction in
GBS EOS by screening all their public patients at
32 weeks gestation and by treating every colonized
parturient. A recent analysis demonstrated that uni-
versal prenatal screening for GBS and chemopro-
phylaxis of colonized women with labor complica-
tions are likely to be cost-beneficial in the United
States.
12
The best management strategy to prevent EOS
GBS has been sought.
13 However, a complete con-
sensus has not been achieved.
14 Recent guidelines
from the American College of Obstetricians and
Gynecologists (ACOG)
is differ from those pro-
mulgated by the Committee on Infectious Diseases
and the Committee on Fetus and Newborn.
10 Spe-
cifically, the ACOG regards screening for GBS as
an option, whereas the pediatric group recommends
screening of all pregnant women. The situation in
which maternal GBS status is unknown and a risk
factor for GBS EOS is present is addressed in a
similar manner by both groups. The ACOG bulle-
tin states that "it may be reasonable to use antibiotic
chemoprophylaxis empirically." The pediatric rec-
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TABLE 2. Data on cases of GBS EOS from the period before the introduction of a protocol for
chemoprophylaxis of GBS EOS (1988-89)
a
Gestational
Age age Risk Intrapartum
Patient (years) G, P (weeks) factors GBS culture Chemoprophylaxis
Neonatal
outcome
32 7, 3 31.2 Preterm P-PROM Positive
2 37 4, 3 32.5 Preterm P-PROM Not done
3 43 8, 4 34.2 Preterm P-PROM Positive
4 34 2, 0 35.4 Preterm P-PROM Negative
S 40 3, 35.7 Preterm P-PROM Not done
6 32 3, 0 38.3 None Not done















3 gravidity, P parity; P-PROM prolonged premature rupture of membranes (>18 h).
ommendation for this situation is that "Chemopro-
phylaxis may be appropriate."
Although there is general agreement with the
need for selective chemoprophylaxis, the feasibility
and effectiveness of implementation have not been
described in the community. A cost-benefit analysis
by Strickland et al.
16 suggested that it would be
cost-effective to provide chemoprophylaxis on the
basis of a rapid test performed during labor. Their
analysis assumed a very rapid turnaround time. It
is not possible to reliably identify women who are
GBS-colonized in the intrapartum period for 2 rea-
sons. First, the diagnostic tests are not adequately
reliable.4,6,17 Second, implementing a rapid diag-
nostic test requires laboratory services around the
clock, which is not feasible in many institutions.
Minkoff and Mead
7 recommended intrapartum
treatment with ampicillin (2 g q 6 h for 24 h) of all
mothers who deliver preterm infants and who are
either carriers of group B beta-hemolytic strepto-
cocci or whose GBS carriage status is unknown.
They
7 did not recommend treating term patients
with P-ROM.
In our study, the incidence ofGBS EOS in both
time periods was lower than that described in other
studies.
18 This may be related to the fact that preg-
nant women in the Los Angeles area and at this
medical center have lower rates of GBS coloniza-
tion (approximately 2.4-5.7%) than described else-
where in the United States (Greenspoon, unpub-
lished data).
17,19,20 The prevalence of GBS
colonization was 22.8% of 5,586 pregnant women
reported by Boyer et al.
19 and 18.6% of 7,742
pregnant women reported by Regan et al.
2 The
low incidence of GBS EOS increases the risk of a
beta error in a study of this size. A larger study is
needed to have the power to demonstrate the statis-
tical significance of small decreases in incidence
rates.
In this study, chemoprophylaxis for preterm
pregnancies at high risk for GBS EOS was admin-
istered more consistently during the 2nd period.
There was a non-significant decrease in the number
of cases among very preterm neonates. The imple-
mentation of an education program for chemopro-
phylaxis did not cause a statistically significant de-
crease in the rate of GBS EOS. The inability to
demonstrate a benefit from chemoprophylaxis is
due to the combination of the inadequate predictive
value of antenatal cultures for intrapartum GBS
colonization (patients and 2, Table 3); non-com-
pliance in administering indicated chemoprophy-
laxis (patients 3 and 5; Table 3); failure of chemo-
prophylaxis or intraamniotic infection treatment to
prevent neonatal infection (patients 6, 8, and 9,
Table 3); and the occurrence of GBS EOS in
infants without risk factors (patients 4 and 7,
Table 3).
Only case of GBS EOS occurred in pregnan-
cies of fewer than 36 weeks gestation during the
2nd time interval when chemoprophylaxis was rec-
ommended. This case involved a patient with a
cervical cerclage who presented in active PTL at 24
weeks. She had a negative genital culture for GBS 5
weeks prior to admission. The patient delivered 25
min after arrival at the hospital. Boyer et al.
18
observed that delivery within h of antibiotic
therapy did not prevent GBS EOS. Thus, this
patientwouldnothavebenefitedfromchemoprophy-
laxis because she delivered too rapidly (patient 1,
Table 3).
The other cases ofGBS EOS involved pregnan-
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TABLE :3. Data on cases of GBS EOS from the period after the introduction of a protocol for
chemoprophylaxis of GBS EOS (1990-91)
a
Gestational
Age age Risk Intrapartum Chemoprophylaxis
Patient (years) G, P (weeks) factors GB$ culture or therapy
Neonatal
outcome
34 5, 2 24.0 Preterm Not done None Died
Negative 5 weeks before delivery
2 25 I, 0 36.0 Preterm Not done None Died
Negative 3 days prior to delivery
3 25 2, 0 36.6 Preterm P PROM Not done None Home, intact
4 30 I, 0 37. None Not done None Home, intact
5 31 I, 0 38.0 P-PROM Not done None Home, intact
6 37 2, 39.0 P-PROM, fever Not done Cefoxitin, gentamicin (penicillin Home, intact
allergy; 2 h prior to delivery)
7 28 2, 39.2 None Not done None Home, intact
8 33 2, 0 39.5 Fever during cesarean section Not done None Home, intact
9 27 2, 41.5 14 h ROM, fever Not done Ampicillin, gentamicin (65 min prior Home, intact
to delivery)
=G gravidity, P parity; P-PROM prolonged premature rupture of membranes (>18 h).
cies at or near term (36 or more completed men-
strual weeks). Some of these cases had P-ROM. In
all cases, it would have been possible after 12 h to
prospectively determine that patients were likely to
haveP-ROM and to initiate chemoprophylaxis dur-
ing labor (patients 3, 5, and 6, Table 3).
We emphasize the association of the induction of
labor forPROM and GBS EOS in 3 of the 9 cases.
Furthermore, a 4th case of GBS EOS was associ-
ated with ROM of 14 h duration in a patient un-
dergoing induction of labor for post-dates preg-
nancy (patient 9, Table 3). Patients who require an
induction of labor for spontaneous PROM may
become candidates for chemoprophylaxis if they do
not deliver within 18 h. It may be prudent to
determine the GBS status of a patient who is likely
to undergo induction of labor within a few days and
whose induction of labor may be complicated by
P-ROM.
Chemoprophylaxis is not of proven benefit in
term pregnancy when the maternal GBS status is
unknown and risk factors are absent. McDuffie et
al.
21 reported adverse perinatal outcomes associated
with resistant Enterobacteriaceae after treatment
with ampicillin or amoxicillin in 4 mothers and
their 5 infants. Further study of the potential ad-
verse effects and their costs is justified. The inci-
dence of GBS EOS in term pregnancy in both
periods approaches the risk for fatal anaphylaxis
due to penicillin therapy, which is approximately
1/10,000 cases.
2z None of the term infants in our
study died or had ongoing disability at the time of
discharge.
CONCLUSIONS
Our experience indicates that a voluntary policy of
chemoprophylaxis for GBS did not decrease the
rate ofGBS EOS. Even if compliance were 100%,
cases ofGBS EOS would continue to occur among
some patients who become GBS-colonized after a
negative antenatal GBS culture; among some pa-
tients in whom appropriate chemoprophylaxis or
therapy for intraamniotic infection is ineffective;
and among GBS-colonized patients without risk
factors. One strategy to decrease the incidence of
GBS EOS is to offer chemoprophylaxis to all colo-
nized patients, including those without risk factors.
This approach should receive careful cost-benefit
and cost-effectiveness analysis before it is recom-
mended. The adverse perinatal outcomes due to
ampicillin-resistant microorganisms should be in-
cluded in any risk-benefit analysis.
21 Thus, despite
empiric chemoprophylaxis, GBS EOS will con-
tinue to occur, albeit infrequently, among parturi-
ents without risk factors.
REFERENCES
1. Vollman JH, Smith WL, Ballard ET, Light IJ: Early
onset group B streptococcal disease: Clinical, roentgeno-
graphic, and pathologic features. J Pediatr 89:199-203,
1976.
214 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGYCHEMOPROPHYLAXIS FOR PREVENTION OF GBS EOS GREENSPOON ET AL.
2. Boyer KM, Gadzala CA, Kelly PD, Gotoff SP: Selective
intrapartum chemoprophylaxis of neonatal group B strep-
tococcal early-onset disease. III. Interruption of mother-
to-infant transmission, j Infect Dis 148:810-816, 1983.
3. Boyer KM, GotoffSP: Prevention ofearly-onset neonatal
group B streptococcal disease with selective intrapartum
chemoprophylaxis. N Engl J Med 314:1665-1669,
1986.
4. Greenspoon JS, Wilcox JG, Kirschbaum TH: Group B
Streptococcus: The effectiveness of screening and chemo-
prophylaxis. Obstet Gynecol Surv 46:499-508, 1991.
5. Anthony BF, Okada DM, Hobel CJ: Epidemiology of
group B Streptococcus: Longitudinal observations during
pregnancy. J Infect Dis 137:524-530, 1978.
6. Yancey MK, Armer T, Clark P, Duff P: Assessment of
rapid identification tests for genital carriage of group B
streptococci. Obstet Gynecol 80:1038-1047, 1992.
7. Minkoff H, Mead P: An obstetric approach to the pre-
vention of early-onset group B beta-hemolytic streptococ-
cal sepsis. Am J Obstet Gynecol 154:973-977, 1986.
8. Mead PB: When to treat intra-amniotic infection (edito-
rial). Obstet Gynecol 72:935-936, 1988.
9. Gardner SB, Winter PD, Gardner MJ: Confidence In-
terval Analysis (CIA). Version 1.0. Br Med J 19-24,
1989.
10. Committee on Infectious Diseases and Committee on Fe-
tus and Newborn: Guidelines for prevention of group B
streptococcal (GBS) infection by chemoprophylaxis. Pedi-
atrics 90:775-780, 1992.
11. Garland SM, Fliegner JR: Group B Streptococcus (GBS)
and neonatal infections: The case for intrapartum prophy-
laxis. Aust NZ J Obstet Gynaecol 31:119-122, 1991.
12. Mohle-Boetani JC, Schuchat A, Plikaytis BD, Smith JD,
Broome CV: Comparison of prevention strategies for neo-
natal group B streptococcal infection: A population-based
economic analysis. JAMA 270:1442-1448, 1993.
13. Gibbs RS, Hall RT, Yow MD, McCracken GH Jr,
NelsonJD: Consensus: Perinatal prophylaxis for group B
streptococcal infection. Pediatr Infect Dis J 11 179-183,
1992.
14. Peter G, Lepow ML, McCracken GH, PhillipsCF (eds):
Group B Streptococcal Infections. Report of the Commit-
tee on Infectious Diseases. 22nd Ed. Elk Grove Village,
IL: American Academy ofPediatrics, pp 447-450, 1991.
15. American College of Obstetrics and Gynecology: Group
B Streptococcal Infections in Pregnancy. ACOG Techni-
cal Bulletin No. 170, pp 1-5, 1992.
16. Strickland DM, Yeomans ER, Hankins GDV: Cost-ef-
fectiveness of intrapartum screening and treatment for
maternal group B streptococci colonization. Am J Obstet
Gynecol 163:4-8, 1990.
17. Greenspoon JS, Fishman A, WilcoxJG, Greenspoon RL,
Lewis W: Comparison of culture for group B Streptococ-
cus versus enzyme immunoassay and latex agglutination
rapid tests: Results in 250 patients during labor. Obstet
Gyneco177:97-100, 1991.
18. Boyer KM, Gadzala CA, Burd LI, Fisher DE, Paton JB,
Gotoff SP: Selective intrapartum chemoprophylaxis of
neonatal group B streptococcal early-onset disease. I. Ep-
idemiologic rationale. J Infect Dis 148:795-801, 1983.
19. Boyer KM, Gadzala CA, Kelly PD, Burd LI, Gotoff SP:
Selective intrapartum chemoprophylaxis of neonatal group
B streptococcal early-onset disease. II. Predictive value of
prenatal cultures. J Infect Dis 148:802-809, 1983.
20. Regan JA, Klebanoff MA, Nugent RP for the Vaginal
Infection and Prematurity Study Group: The epidemiol-
ogy of group B streptococcal colonization in pregnancy.
Obstet Gynecol 77:604-610, 1991.
21. McDuffie RS, McGregor JA, Gibbs RS: Adverse peri-
natal outcome and resistant Enterobacteriaceae after anti-
biotic usage for premature rupture of the membranes and
group B Streptococcus carriage. Obstet Gynecol 82:487-
489, 1993.
22. Goodman LS, Gilman AG (eds): Goodman and Gilman’s
The Pharmacological Basis ofTherapeutics. 8th Ed. New
York: Pergamon Press, 1990.
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY